Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationDual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid TumorsDiscovering and understanding oncogenic gene fusions through data intensive computational approachesDetermining Cysteines Available for Covalent Inhibition Across the Human Kinome.Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells.Covalent targeting of acquired cysteines in cancerIlluminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Allosteric inhibition of antiapoptotic MCL-1.Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.New drug design with covalent modifiers.Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.FGFR-targeted therapeutics for the treatment of breast cancer.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Advances and challenges in targeting FGFR signalling in cancer.Emerging molecular therapeutic targets for cholangiocarcinoma.Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design.FGFR1 and FGFR2 in fibrolamellar carcinoma.Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.Targeting cholangiocarcinoma.FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition.
P2860
Q26768158-F29C2F1E-1A81-4B8C-835B-7D1C15D3D0F9Q28079309-7D5D4427-80FA-4C2C-9A12-6B4FB61733ADQ28822011-821A1BD4-0FD1-4D49-81F9-984BEC250693Q31083417-1CC80458-7ADB-454F-89A0-761B9DF8F6E3Q33859476-11A252FC-4EB0-44A8-876A-BEF04A110BBAQ34469971-AC35DDD6-AE03-4492-A90D-AEC184823E84Q35752926-6F0BF842-7889-4064-84CB-358BD7065525Q35808066-65703FF8-D455-4EF4-9C02-A9D336157778Q35858612-C953C377-D8D3-487D-87B4-1D955CEC7801Q35944914-BBD5097B-4E0D-4C22-AEEB-369733C40286Q36012325-3316E823-DBD2-4F92-9B99-D30B45FAD727Q36129968-7DDDD69E-0EF9-4C52-87D8-9299A56D2009Q36983860-73D31988-9DF2-4092-B146-CA230FDF4B1BQ37696325-F4039E3E-AF84-4FBE-837B-22EFE69DD5CEQ38693434-38B25790-7269-4E45-AEF0-AE77BE871420Q38760333-EED10BBD-FAD1-4C6E-BEEB-2FD5253950E0Q38766035-A1FC793A-73E6-46AA-848D-5A43E29B66E7Q38776411-EE84F77C-E923-4F0C-B633-A5BA3261F5B3Q38825945-994B6C9E-92A1-4A63-B5A9-923C48641B49Q38989374-84006DEE-ED9E-4194-9E3C-7138901245C7Q39183442-19340F86-E509-48CF-9EE7-651F5181DF8EQ39227356-7B8316D5-FD1E-4E33-84B4-2C17D3BF41A6Q39296374-A4F3DEC2-E0A6-4C46-A722-85C107D1332FQ40640497-774FF6DC-EED1-417C-80B2-88F33041356CQ42343453-2B272FEB-6DBF-4F0A-B1F1-FD83BA971AA7Q48125728-820E2B72-3AEE-4B08-9CA4-8A790F8D5D31Q48227433-F9B5164F-20B3-4CAC-A57B-1EB3BE53F3BAQ52589214-71A9365C-6585-4022-9992-83C4B72F80CAQ52757760-ECE3DD12-842C-4E00-BB99-FFC3A8689491Q52960616-C7F19EA1-BD30-49CB-ACE7-46F0F247B794
P2860
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@ast
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@en
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@nl
type
label
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@ast
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@en
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@nl
prefLabel
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@ast
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@en
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@nl
P2093
P2860
P50
P356
P1476
Development of covalent inhibi ...... ration FGFR kinase inhibitors.
@en
P2093
Amir R Aref
Cai-Hong Yun
Dalia Ercan
David A Barbie
Jing-Ruey Joanna Yeh
Junko Tanizaki
Maria Rusan
NamDoo Kim
P2860
P304
P356
10.1073/PNAS.1403438111
P407
P577
2014-10-27T00:00:00Z